Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Grail securities between May 13, 2025 and February 19, 2026. The complaint claims defendants misrepresented the likelihood of achieving the primary endpoint in the NHS-Galleri trial, overstated optimism about the study, and made misleading statements based on positive top-line results while ignoring contrary data trends. Investors have until August 4, 2026 to seek lead plaintiff appointment.
GRAIL, LLCClass action lawsuit alleging securities law violations for misrepresenting trial endpoint likelihood and misleading statements.